Table 1.
Clinicopathological features of BC patients
| Characteristics | Discovery cohort (n = 100) | Validation cohort (n = 1880) |
|---|---|---|
| Age at diagnosis | ||
| − 20 | 5 (5%) | 1 (0.05%) |
| 21–30 | 95 (95%) | 111 (5.9%) |
| 31–40 | 804 (42.7%) | |
| 41–50 | 964 (51.3%) | |
| Sex | ||
| Female | 100 (100%) | 1880 (100%) |
| Male | 0 | 0 |
| Race | ||
| White (Slavic) population) | 100 (100%) | 1880 (100%) |
| Hormone receptor status | ||
| ER | 33 (33%) | 695 (37%) |
| PgR | 28 (28%) | 752 (40%) |
| HER2 | 21 (21%) | 211 (11.2%) |
| Triple negative | 9 (9%) | 162 (8.6%) |
| Unknown | 9 (9%) | 60 (3.2%) |
| Status | ||
| Alive | 88 (88%) | 1710 (91%) |
| Dead | 12 (12%) | 170 (9%) |
| Histopathological type | ||
| Ductal carcinoma | 54 (54%) | 950 (50.5%) |
| Lobular carcinoma | 4 (4%) | 105 (5.6%) |
| Medullary carcinoma | 3 (3%) | 77 (4.1%) |
| DCIS | 2 (2%) | 55(2.9%) |
| Others | 10 (10%) | 130 (6.9%) |
| Unknown | 27 (27%) | 563 (29.9%) |